CABLIVI (caplacizumab-yhdp) logo

Menu

Resources for your patients


Downloadable resources

To share with your patients with acquired/immune-mediated thrombotic thrombocytopenic purpura (aTTP/iTTP) who are receiving or interested in CABLIVI® (caplacizumab-yhdp)

CABLIVI (caplacizumab-yhdp) Patient Brochure thumbnail

CABLIVI Patient Brochure

CABLIVI product information for your patients.

DOWNLOAD
CABLIVI (caplacizumab-yhdp) Patient Enrollment Form thumbnail

CABLIVI Patient Enrollment Form

Enroll patients in CABLIVI Patient Solutions for access to specialty pharmacy services, financial assistance, and supplemental training.

DOWNLOAD
CABLIVI (caplacizumab-yhdp) Patient Solutions thumbnail

CABLIVI Patient Solutions

Learn about the support offered through CABLIVI Patient Solutions.

DOWNLOAD
CABLIVI (caplacizumab-yhdp) Administration Training Guide thumbnail

CABLIVI Supplemental Administration Training Guide

Information to share with your patients regarding the administration of CABLIVI.

DOWNLOAD
Hand holding gear symbol

For more support for your patients, enroll them in CABLIVI Patient Solutions

From hospital to home icon

Ease the transition from hospital to home

INDICATIONS

CABLIVI (caplacizumab-yhdp) is indicated for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS:

CABLIVI is contraindicated in patients with a previous severe hypersensitivity reaction to caplacizumab-yhdp or to any of its excipients. Hypersensitivity reactions have included urticaria.

WARNINGS AND PRECAUTIONS:

Hemorrhage:

  • CABLIVI increases the risk of bleeding. In clinical studies, severe bleeding adverse reactions of epistaxis, gingival bleeding, upper gastrointestinal hemorrhage, and metrorrhagia were each reported in 1% of subjects. Overall, bleeding events occurred in approximately 58% of patients on CABLIVI versus 43% of patients on placebo.
  • In the postmarketing setting cases of life-threatening and fatal bleeding were reported in patients receiving CABLIVI.
  • The risk of bleeding is increased in patients with underlying coagulopathies (e.g. hemophilia, other coagulation factor deficiencies). It is also increased with concomitant use of CABLIVI with drugs affecting hemostasis and coagulation.
  • Avoid concomitant use of CABLIVI with antiplatelet agents or anticoagulants. If clinically significant bleeding occurs, interrupt use of CABLIVI. Von Willebrand factor concentrate may be administered to rapidly correct hemostasis. If CABLIVI is restarted, monitor closely for signs of bleeding.
  • Withhold CABLIVI for 7 days prior to elective surgery, dental procedures or other invasive interventions. If emergency surgery is needed, the use of von Willebrand factor concentrate may be considered to correct hemostasis. After the risk of surgical bleeding has resolved, and CABLIVI is resumed, monitor closely for signs of bleeding. 

ADVERSE REACTIONS:

The most common adverse reactions (>15% of patients) were epistaxis (29%), headache (21%) and gingival bleeding (16%).

CONCOMITANT USE OF ANTICOAGULANTS OR ANTIPLATELET AGENTS:

Concomitant use of CABLIVI with any anticoagulant or antiplatelet agent may increase the risk of bleeding. Avoid concomitant use when possible. Assess and monitor closely for bleeding with concomitant use.

PREGNANCY:

There are no available data on CABLIVI use in pregnant women to inform a drug associated risk of major birth defects and miscarriage.

  • Fetal/neonatal adverse reactions: CABLIVI may increase the risk of bleeding in the fetus and neonate. Monitor neonates for bleeding.
  • Maternal adverse reactions: All patients receiving CABLIVI, including pregnant women, are at risk for bleeding. Pregnant women receiving CABLIVI should be carefully monitored for evidence of excessive bleeding.

INDICATIONS

IMPORTANT SAFETY INFORMATION

CABLIVI and Sanofi are registered trademarks of Sanofi or an affiliate. MAT-US-2303013-v2.0-05/2025 Last Updated: May 2025.